Kyowa Hakko Kogyo Co., a Japanese biotechnology and pharmaceutical company, announced Monday the creation of a new unit in the United States to develop and market monoclonal antibodies and other biological technologies and businesses.
Kyowa Hakko, the nation’s largest fermented-chemical company, said BioWa Inc., a wholly owned subsidiary in Princeton, N.J., of Kyowa America Inc., is intended to tap the rapidly growing antibody therapeutic industry with antibody medicines.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.